HCC: Current State, Available and Emerging Therapies – Episode 1

PCE

Feb 25, 2022•33 min•Ep. 34

--:--

Listen in podcast apps:

Apple Podcasts

Spotify

Download

Listen to this episode in Metacast mobile app

Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

In this first episode of two podcasts, Dr. Amit Singal and Dr. Mark Yarchoan discuss the latest data supporting their approach to selecting treatment regimens for patients with HCC, with topics including: the current challenges in the management of HCC, recommended initial workup strategies and the evolving treatment landscape in HCC. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributors:

Amit Singal, MD, MS

Mark Yarchoan, MD

Bridget O’Brien, DNP, FNP-BC, AOCNP

Dr Singal: consulting fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Roche.

Dr Yarchoan: consulting fees: AstraZeneca, Eisai, Exelixis, Genentech; other financial or material support: Bristol-Myers Squibb, Incyte.

Dr O’Brien: fees for non-CME/CE services: Amgen, Novartis.

For the best experience, listen in Metacast app for iOS or Android